Literature DB >> 28891101

The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.

Jyotika D Prasad1,2,3, Annabelle Mahar4, Jane Bleasel5,6, Samantha J Ellis7, Daniel C Chambers8,9, Fiona Lake10,11, Peter M A Hopkins8,9, Tamera J Corte12,13, Heather Allan14, Ian N Glaspole1,3.   

Abstract

Interstitial lung diseases (ILD) are a diverse group of pulmonary diseases for which accurate diagnosis is critical for optimal treatment outcomes. Diagnosis of ILD can be challenging and a multidisciplinary approach is recommended in international guidelines. The purpose of this position paper is to review the evidence for the use of the multidisciplinary meeting (MDM) in ILD and suggest an approach to its governance and constitution, in an attempt to provide a standard methodology that could be applied across Australia and New Zealand. This position paper is endorsed by the Thoracic Society of Australia and New Zealand (TSANZ) and the Lung Foundation Australia (LFA).
© 2017 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.

Entities:  

Keywords:  clinical respiratory medicine; interstitial lung disease; multidisciplinary meeting; pulmonary fibrosis; rare lung diseases

Mesh:

Year:  2017        PMID: 28891101     DOI: 10.1111/resp.13163

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  11 in total

1.  Impact of an interstitial lung disease service in the diagnosis and management of interstitial lung disease in Singapore.

Authors:  Gin Tsen Chai; Teck Choon Tan; Yeong Shyan Lee; Gregory Jl Kaw; Khoon Leong Chuah; Yi Jing Lim; John Arputhan Abisheganaden; Bernard Yh Thong
Journal:  Singapore Med J       Date:  2019-07-11       Impact factor: 1.858

2.  Diagnosis from Afar: Is Remote Multidisciplinary Discussion Appropriate for Interstitial Lung Disease Care?

Authors:  Eleanor Valenzi; Daniel J Kass
Journal:  Ann Am Thorac Soc       Date:  2019-04

Review 3.  Idiopathic and immune-related pulmonary fibrosis: diagnostic and therapeutic challenges.

Authors:  Andrew McLean-Tooke; Irene Moore; Fiona Lake
Journal:  Clin Transl Immunology       Date:  2019-11-05

4.  Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand.

Authors:  Adelle S Jee; Robert Sheehy; Peter Hopkins; Tamera J Corte; Christopher Grainge; Lauren K Troy; Karen Symons; Lissa M Spencer; Paul N Reynolds; Sally Chapman; Sally de Boer; Taryn Reddy; Anne E Holland; Daniel C Chambers; Ian N Glaspole; Helen E Jo; Jane F Bleasel; Jeremy P Wrobel; Leona Dowman; Matthew J S Parker; Margaret L Wilsher; Nicole S L Goh; Yuben Moodley; Gregory J Keir
Journal:  Respirology       Date:  2020-11-24       Impact factor: 6.424

5.  Clinical characteristics and prognostic risk factors of mortality in patients with interstitial lung diseases and viral infection: a retrospective cohort study.

Authors:  Lijuan Li; Chulei Wang; Lingxiao Sun; Xiaoqi Zhang; Guoru Yang
Journal:  J Med Microbiol       Date:  2021-11       Impact factor: 2.472

6.  TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis.

Authors:  John A Mackintosh; Maria Pietsch; Viviana Lutzky; Debra Enever; Sandra Bancroft; Simon H Apte; Maxine Tan; Stephanie T Yerkovich; Joanne L Dickinson; Hilda A Pickett; Hiran Selvadurai; Christopher Grainge; Nicole S Goh; Peter Hopkins; Ian Glaspole; Paul N Reynolds; Jeremy Wrobel; Adam Jaffe; Tamera J Corte; Daniel C Chambers
Journal:  BMJ Open Respir Res       Date:  2021-12

7.  A Systematic Review of the Development and Implementation of Needs-Based Palliative Care Tools in Heart Failure and Chronic Respiratory Disease.

Authors:  Amy Waller; Breanne Hobden; Kristy Fakes; Katherine Clark
Journal:  Front Cardiovasc Med       Date:  2022-04-13

8.  Real world utilization of the myositis autoantibody panel.

Authors:  Mithu Maheswaranathan; Andrew Johannemann; Jason J Weiner; Ryan Jessee; Amanda M Eudy; Lisa Criscione-Schreiber
Journal:  Clin Rheumatol       Date:  2021-02-24       Impact factor: 2.980

9.  A comprehensive assessment of environmental exposures and the medical history guides multidisciplinary discussion in interstitial lung disease.

Authors:  Neal Dodia; Diana Amariei; Blaine Kenaa; Doug Corwin; Lydia Chelala; E James Britt; Ashutosh Sachdeva; Irina G Luzina; Jeffrey D Hasday; Nirav G Shah; Sergei P Atamas; Teri J Franks; Allen P Burke; Stella E Hines; Jeffrey R Galvin; Nevins W Todd
Journal:  Respir Med       Date:  2021-02-11       Impact factor: 3.415

10.  CXCR4+ cells are increased in lung tissue of patients with idiopathic pulmonary fibrosis.

Authors:  Jade Jaffar; Kate Griffiths; Sara Oveissi; Mubing Duan; Michael Foley; Ian Glaspole; Karen Symons; Louise Organ; Glen Westall
Journal:  Respir Res       Date:  2020-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.